目的：探讨桂枝茯苓丸对子宫内皮异位症患者在位和异位内膜组织低氧诱导因子-1α（HIF-1α）和血管内皮生长因子（VEGF）的影响。方法：2011年6月~2013年6月间西宁市第一人民医院子宫异位症患者68例，所有患者均接受桂枝茯苓丸治疗，1次/日，连续治疗1个月后对其疗效进行评估，并于治疗前后取在位和异位内膜组织，采用SP法对患者内膜组织中HIF-1α和VEGF蛋白水平和相关性进行分析。结果：桂枝茯苓丸治疗EM的总有效率为86.76%。与治疗前比较，治疗后异位和在位内膜组织HIF-1α和VEGF蛋白水平明显下降（P<0.05）。VEGF蛋白下降与HIF-1α表达水平呈正相关（P<0.05）。结论：桂枝茯苓丸治疗子宫内膜异位症具有较好的效果，其中异位内膜组织中HIF-1α和VEGF水平下调可能是导致该结果的原因之一。

This study was aimed to explore effect of Gui-Zhi Fu-Ling Wan (GZFLW) on HIF-1α and vascular endothelial growth factor (VEGF) in patients with endometriosis. A total of 68 endometriosis patients in the First People's Hospital of Xining from June 2011 to June 2013 were included. All patients received treatment of GZFLW, once a day. After one-month treatment, the treatment efficacy was analyzed. The endometrial tissues (both ectopic endometrium and eutopic endometrium) were obtained before and after treatment. The protein levels of HIF-1α and VEGF as well as the relationship of HIF-1α and VEGF were analyzed by SP immunohistochemistry. The results showed that the total treatment efficacy was 86.76%. Compared with pretreatment, the posttreatment protein levels of HIF-1α and VEGF were significantly reduced (P < 0.05). The decreasing of VEGF protein level and HIF-1α expression level were positively correlated(P < 0.05). It was concluded that GZFLW had better efficacy in the treatment of endometriosis. One of the reasons may be the downregulation of protein levels of HIF-1α and VEGF in endometriosis tissues.

教育部中央高校基本科研业务费专项（1508219042）：盆底功能重建软组织修复材料的研究——脐血间充质干细胞转染NF1后构建生物复合材料在盆底重建中的研究，负责人：王建军。